Fact Sheet: The 340B Drug Pricing Program

At a Glance

The Issue

For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients. These organizations include community health centers, children’s hospitals, hemophilia treatment centers, critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), and public and nonprofit disproportionate share hospitals (DSH) that serve low-income and indigent populations.

The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs.

According to the Health Resources and Services Administration (HRSA), which is responsible for administering the 340B program, enrolled hospitals and other covered entities can achieve average savings of 25 to 50% in pharmaceutical purchases. Despite increased oversight from HRSA and the program’s proven record of decreasing government spending and expanding access to patient care, some want to scale it back or significantly reduce the benefits that eligible hospitals and their patients receive from the program.

AHA Position

  • The 340B program is essential to helping providers stretch limited resources to better serve their vulnerable communities.
  • HHS must rescind the drastic and unlawful Medicare payment cuts for many hospitals in the 340B program and expand drug manufacturer transparency.
  • Drug manufacturers must not be permitted to unilaterally and unlawfully change the 340B program.
  • 340B hospitals must have flexibility in meeting the program’s eligibility requirements during the COVID-19 pandemic to account for temporary changes in patient mix.
  • Supports eliminating the orphan drug exclusion for certain 340B hospitals.
  • Opposes efforts to scale back, significantly reduce the benefits of, or expand the regulatory burden of the 340B program, including proposals to dramatically expand reporting requirements on certain 340B hospitals and impose a moratorium on new entrants into the program.
  • Supports expanding the program to reach additional vulnerable communities, including investor-owned hospitals that provide care for underserved populations.
  • Supports voluntary program integrity efforts already underway to ensure this vital program remains available to safetynet providers.

View the entire Fact Sheet under Key Resources. 

Related Resources

Guides/Reports
Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990…
Fact Sheets
Public
The COVID-19 pandemic has altered hospitals’ payer mix, which for some hospitals has temporarily lowered their disproportionate share hospital (DSH) percentage…
Special Bulletin
Public
Download the AHA Special Bulletin: CMS Issues Hospital Outpatient/ASC Proposed Rule, Including Modifications to Price Transparency Rule
Advancing Health Podcast
Public
Columbus, Ohio-based Mount Carmel Health System goes beyond the walls of its hospital to serve its community and patients through programs such as Street…
Letter/Comment
Public
Amy Bricker President Express Scripts PBM 1 Express Way Saint Louis, MO 63121 Dear Ms. Bricker:
Action Alert
Member
Please contact your members of Congress and urge them to support legislation that will provide certainty to hospitals participating in the 340B Drug Pricing…